Results 1 to 10 of about 2,906,691 (234)

Primary cytoreductive surgery or interval cytoreductive surgery

Taiwanese Journal of Obstetrics and Gynecology
Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
openaire   +4 more sources

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been associated with encouraging survival results in some patients with colorectal peritoneal metastases who were eligible for complete macroscopic ...
F. Quénet, D. Elias, L. Roca, D. Goéré, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, B. Juzyna, H. De forges, J. Paineau, O. Glehen   +16 more
semanticscholar   +1 more source

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Journal of Clinical Oncology, 2023
PURPOSE In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled,
B. Rau, Hauke Lang, Alfred Koenigsrainer, Ines Gockel, H. Rau, H. Seeliger, C. Lerchenmueller, D. Reim, Roger Wahba, Martin Angele, S. Heeg, Tobias Keck, A. Weimann, S. Topp, P. Piso, A. Brandl, Silke Schuele, Peter Jo, J. Pratschke, S. Wegel, A. Rehders, N. Moosmann, J. Gaedcke, Volker Heinemann, E. Trips, Markus Loeffler, P. Schlag, P. Thuss-Patience   +27 more
semanticscholar   +1 more source

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone
S. Aronson, M. Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, M. V. van Gent, H. Arts, M. van Ham, P. V. van Dam, P. Vuylsteke, A. Aalbers, V. Verwaal, K. K. van de Vijver, N. Aaronson, G. Sonke, W. V. van Driel   +17 more
semanticscholar   +1 more source

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer

JAMA Surgery, 2022
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer?
M. Lim, Suk-Joon Chang, Boram Park, H. Yoo, C. Yoo, B. Nam, Sang-Yoon Park   +6 more
semanticscholar   +1 more source

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

New England Journal of Medicine, 2021
BACKGROUND Treatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear.
P. Harter, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, Berit J. Mosgard, F. Selle, F. Guyon, C. Pomel, F. Lécuru, R. Zang, E. Åvall-Lundqvist, Jae-Weon Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J. Classe, P. Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem-Maghami, M. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, A. du Bois   +29 more
semanticscholar   +1 more source

Enhanced Recovery after Surgery (ERAS) Program for Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery with or without HIPEC: A Systematic Review and a Meta-Analysis

Cancers, 2023
Simple Summary Cytoreductive surgery and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) represent a promising treatment strategy for the management of selected cases of peritoneal cancer, but it’s still burdened by significant morbidity and prolonged ...
M. Robella, M. Tonello, P. Berchialla, V. Sciannameo, Alba Ilari Civit, A. Sommariva, C. Sassaroli, A. di Giorgio, R. Gelmini, V. Ghirardi, F. Roviello, F. Carboni, P. Lippolis, S. Kusamura, M. Vaira   +14 more
semanticscholar   +1 more source

The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.

JAMA Surgery, 2021
Importance Studies on the prognostic role of hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei (PMP) are currently not available.
S. Kusamura, F. Barretta, Y. Yonemura, P. Sugarbaker, B. Moran, E. Levine, D. Goéré, D. Baratti, E. Nizri, D. Morris, O. Glehen, A. Sardi, P. Barrios, F. Quénet, L. Villeneuve, A. Gómez-Portilla, I. D. de Hingh, W. Ceelen, J. Pelz, P. Piso, S. González-Moreno, K. van der Speeten, M. Deraco   +22 more
semanticscholar   +1 more source

Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis

Journal of Gynecologic Oncology, 2022
Objective Advances in ovarian cancer cytoreductive surgery have enabled more extensive procedures to achieve maximal cytoreduction but with a consequent increase in postoperative morbidity and mortality.
M. Kengsakul, G. N. Nieuwenhuyzen-de Boer, S. Udomkarnjananun, S. J. Kerr, C. Niehot, H. V. van Beekhuizen   +5 more
semanticscholar   +1 more source

Cytoreductive Surgery [PDF]

Definitions, 2020
openaire   +2 more sources